Nikitin Pavel V, Ryzhova Marina V, Shishkina Lyudmila V, Shugay Svetlana V, Zubova Irina V
Department of Neuropathology and Molecular Diagnostics, N.N. Burdenko Neurosurgical Institute, Moscow, Russia.
Department of Neuropathology and Molecular Diagnostics, N.N. Burdenko Neurosurgical Institute, Moscow, Russia.
World Neurosurg. 2019 Feb;122:e1047-e1051. doi: 10.1016/j.wneu.2018.10.225. Epub 2018 Nov 9.
Immunohistochemistry is a basic diagnostic technique. Immunohistochemical examination results reflect mainly qualitative and less quantitative characteristics of proteomic status of cells. A combined approach with complex quantitative evaluation of marker expression using colorimetric analysis and computer technologies can expand the diagnostic capabilities of immunohistochemistry. We studied such an approach developed by using expression of the proliferative marker Ki-67 in pituitary adenomas.
A retrospective, blind, randomized, comparative study was performed of Ki-67 expression activity in pituitary adenomas using the traditional Ki-67 labeling index and a simple immunohistochemical cytocolorimetric analysis developed by us with immunohistochemical cytocolorimetric index (ICI) estimation as predictors of relapse, assessing the relationships of these indicators with the time before relapse.
Mean Ki-67 labeling index was 3.87% ± 0.29% in the relapse-free group and 4.01% ± 0.29% in the relapse group; the difference was not statistically significant. The average Ki-67 ICI was 24.16% ± 0.51% in the relapse-free group and 30.68% ± 0.64% in the relapse group; the difference was statistically significant. The correlation coefficient of ICI values and time before relapse was -0.302, indicating the presence of a weak negative correlation.
We successfully tested an ICI estimation method developed by us to assess Ki-67 expression in pituitary adenomas. The ICI technique can be used both as a prognostic factor for relapse and, in combination with other modern proteomic and genetic methods, as the basis for creation of new multimodal analyzing systems for functional state assessment of cells and tissues.
免疫组织化学是一种基本的诊断技术。免疫组织化学检查结果主要反映细胞蛋白质组状态的定性特征，定量特征较少。采用比色分析和计算机技术对标志物表达进行复杂定量评估的联合方法，可以扩展免疫组织化学的诊断能力。我们研究了一种通过垂体腺瘤中增殖标志物Ki-67的表达开发的方法。
采用传统的Ki-67标记指数和我们开发的简单免疫组织化学细胞比色分析方法，以免疫组织化学细胞比色指数（ICI）估计作为复发预测指标，对垂体腺瘤中Ki-67的表达活性进行回顾性、盲法、随机、对照研究，评估这些指标与复发前时间的关系。
无复发组的平均Ki-67标记指数为3.87%±0.29%，复发组为4.01%±0.29%；差异无统计学意义。无复发组的平均Ki-67 ICI为24.16%±0.51%，复发组为30.68%±0.64%；差异有统计学意义。ICI值与复发前时间的相关系数为-0.302，表明存在弱负相关。
我们成功测试了我们开发的一种ICI估计方法，用于评估垂体腺瘤中Ki-67的表达。ICI技术既可以作为复发的预后因素，也可以与其他现代蛋白质组学和遗传学方法结合，作为创建用于评估细胞和组织功能状态的新型多模态分析系统的基础。
